Navigation Links
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Date:11/29/2007

months; and that there is clinically significant impairment in social, academic or occupational functioning and the symptoms cannot be better explained by another psychiatric disorder.

Although there is no "cure" for ADHD, there are accepted treatments that specifically target its symptoms. The most common standard treatments include educational approaches, psychological or behavioral modification, and medication.

About VYVANSE

Tell the doctor about any heart conditions, including structural abnormalities, that you, your child, or a family member, may have. Inform the doctor immediately if your child develops symptoms that suggest heart problems, such as chest pain or fainting.

VYVANSE should not be taken if your child has advanced disease of the blood vessels (arteriosclerosis); symptomatic heart disease; moderate to severe high blood pressure; overactive thyroid gland (hyperthyroidism); known allergy or unusual reactions to drugs called sympathomimetic amines (for example, pseudoephedrine); seizures; glaucoma; a history of problems with alcohol or drugs; agitated states; taken a monoamine oxidase inhibitor (MAOI) within the last 14 days.

Tell the doctor before taking VYVANSE if your child is being treated for or has symptoms of depression (sadness, worthlessness, or hopelessness) or bipolar disorder; has abnormal thought or visions, hears abnormal sounds, or has been diagnosed with psychosis; has had seizures or abnormal EEGs; has or has had high blood pressure; exhibits aggressive behavior or hostility. Tell the doctor immediately if your child develops any of these conditions or symptoms while taking VYVANSE.

Abuse of amphetamines may lead to dependence. Misuse of amphetamine may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use.

VYVANSE was generally well tolerated in clinical studies. The most common side effects reported in studies of
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...Puhua Hospital Stem Cells Center ( http://www.stem...em cells to effectively treat neurological disorde...dditions to its medical and research staff that si...lities for growing numbers of incoming internation...stinguished Dr. Jiang Ping, who was named Chief Sc...
(Date:1/6/2009)... -- The Michael J. Fox Foundation awarded a total ...ams for pre-clinical research on potential new tre...g was awarded under the Foundation,s Therapeutics...ched in 2006, supports and bolsters industry-focus...of MJFF,s focus on ,de-risking, preclinical PD r...
(Date:1/5/2009)... Pharmaceuticals announced today that it has initi...ein kinase inhibitor, CX-4945, in patients with ad...ple myeloma. The primary endpoints of the oral dos...lerance and PK properties of CX-4945 and to select...tion, multiple mechanism-related pharmacodynamic b...
(Date:12/29/2008)...swire/ -- The winner of the 2008 Award for Excelle...ay by Dr. Peter G. Goldschmidt, President and Foun...he winner of the annual award was the Universit...ts best practice " IND Regulatory and Monitoring P...man subjects protection, 2) improved data quality ...
Breaking Medicine Technology:Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 1Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 2Institute for Integrative Nutrition Joshua Rosenthal Attract Nations Top Health Wellness Experts 11772 3Winner Medical Reports First Quarter Fiscal 2008 Results 11770 1Winner Medical Reports First Quarter Fiscal 2008 Results 11770 2Winner Medical Reports First Quarter Fiscal 2008 Results 11770 3Winner Medical Reports First Quarter Fiscal 2008 Results 11770 4Winner Medical Reports First Quarter Fiscal 2008 Results 11770 5Winner Medical Reports First Quarter Fiscal 2008 Results 11770 6Winner Medical Reports First Quarter Fiscal 2008 Results 11770 7Winner Medical Reports First Quarter Fiscal 2008 Results 11770 8Winner Medical Reports First Quarter Fiscal 2008 Results 11770 9Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 1Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 2Elsevier Foundation Announces Grants for Innovative Libraries and New Scholars 11768 3GeneGo Collaborates With The Netherlands Toxicogenomics Center on 24100 Million Grant 3253 1GeneGo Collaborates With The Netherlands Toxicogenomics Center on 24100 Million Grant 3253 2
...rstCall/--,EntreMed, Inc. , a clinical-stage pharm...treatment of cancer and inflammatory diseases,tod...ts for MKC-1,its novel cell cycle inhibitor. The ...American Association for Cancer Research (AACR),An...California. , MKC-1 is a novel, orally-active cell...
...ansurethral Resection,is Well Tolerated in Phase 2...2007 /PRNewswire-FirstCall/ --,Spectrum Pharmaceut... study of EOquin, in non-invasive bladder cancer a...L)-1620 and satraplatin,at the annual meeting of t...t the Los Angeles Convention Center in Los Angeles...
Other Medicine Technology:EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 2EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 3EntreMed Presents Preclinical Data for MKC-1 in Hematological,Cancers 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 2Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 3Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 4Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 5Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 6Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 7Spectrum Pharmaceuticals Announces Data From Three Oncology,Programs Presented at the American Association of Cancer Research,Annual Meeting 8
(Date:1/8/2009)...wswire-FirstCall/ -- Allscripts-Misys Healthcare,...lutions, Inc. (Allscripts or,the Company), today ...six,months ended November 30, 2008. , (Log...LLSCRIPTSLOGO-b ) , The Company,s results f...8,include results from legacy Allscripts for the ...
(Date:1/8/2009)...RNewswire-USNewswire/ -- A new educational Web sit...on drugs, biological products and medical devices ...y,s Centers for Education and Research on Therapeu...e than a dozen leading research centers nationwide...ion Network ( CHAIN ) http://www.chainonline.org ...
(Date:1/8/2009)...PRNewswire-FirstCall/ -- Heska Corporation (Nasdaq..., , What: Heska Corporation Invites You to...nd 2008 Earnings Conference Call on the Web, ...], Where: www.heska.com (click on the Q4 ...k on the front page of this website)., How: ...
(Date:1/8/2009)...sile Strikes , , NEW YORK, Jan. 8 /PRNewswire-... the Jewish Federations of North America today com...n and social needs in southern Israel, part of a m... with Israelis during the current conflict with Ha...Gaza Strip. , , The funds will enhance program...
Breaking Medicine News(10 mins):Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2Health News:UJC and Jewish Federations of North America Commit $10 Million for Needs in Southern Israel 2
...ia were diagnosed with severe symptoms of cholera.... prison are hospitalized after they showed symptom...Doctors, health officials and the prison officials...result in a cholera endemic. Cholera is a water b...
... is a significant reduction in the case of cardiov...both in the case of men and women. In the case of ...while in the case of women, the possibilities of s...role of aspirin in bringing down such risks are no...
...was arrested after the death of her patient. Dr S...last Friday and was released on bail. // She had b...ondon. Dr Dhar was arrested and was charged for ma...e and depraving the course of justice. Her patien...
...ery upset and has sent a letter to the acting head...on Eschenbach. In his letter he had asked the FDA ...onfusion started when it was reveled that the tain...n case of tissue transplants. Schumer asked the fe...
Other Medicine News:
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
...l reference laboratory and a worldwide leader in i...P offers an extensive test menu of highly complex ...pathology. Owned by the University of Utah, ARUP L... nation's university teaching hospitals and childr...
Medicine Products: